Altrius Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.7M Buy
203,089
+6,115
+3% +$163K 1.13% 45
2025
Q4
$4.9M Buy
196,974
+3,454
+2% +$87.1K 1.04% 60
2025
Q3
$4.93M Buy
193,520
+6,490
+3% +$160K 1.12% 51
2025
Q2
$4.53M Buy
187,030
+12,380
+7% +$289K 1.06% 50
2025
Q1
$4.43M Buy
174,650
+5,016
+3% +$131K 1.08% 54
2024
Q4
$4.5M Buy
169,634
+17,050
+11% +$462K 1.21% 44
2024
Q3
$4.42M Buy
152,584
+4,350
+3% +$127K 1.11% 58
2024
Q2
$4.15M Buy
148,234
+2,330
+2% +$64.1K 1.09% 55
2024
Q1
$4.05M Buy
145,904
+13,888
+11% +$385K 1.02% 58
2023
Q4
$3.8M Buy
132,016
+34,783
+36% +$1.05M 1.06% 50
2023
Q3
$3.23M Buy
97,233
+13,169
+16% +$466K 0.96% 59
2023
Q2
$3.08M Buy
84,064
+1,842
+2% +$71.7K 0.91% 63
2023
Q1
$3.35M Buy
82,222
+15,411
+23% +$666K 1.03% 49
2022
Q4
$3.42M Sell
66,811
-2,036
-3% -$97.6K 1.07% 44
2022
Q3
$3.01M Sell
68,847
-32,923
-32% -$1.6M 1.15% 34
2022
Q2
$5.33M Buy
+101,770
New +$5.19M 1.73% 5

Other funds holding PFE

Altrius Capital Management's PFE Position: Q1 2026 in Review

Altrius Capital Management increased its Pfizer (PFE) stake by 3.1% in Q1 2026, buying an estimated $163K and bringing the position to 203,089 shares worth $5.7M. The position accounts for 1.13% of the portfolio, ranked #45.

Altrius Capital Management first reported a position in PFE in Q2 2022 and has held it in 16 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Altrius Capital Management held 203,089 shares of Pfizer worth $5.7M as of Q1 2026.
  • Altrius Capital Management bought 6,115 Pfizer shares in Q1 2026, an estimated $163K.
  • Pfizer made up 1.13% of Altrius Capital Management's portfolio in Q1 2026, its #45 holding.
  • Altrius Capital Management first reported a position in Pfizer in Q2 2022 and has held it in 16 quarters since.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Altrius Capital Management's 13F filing for Q1 2026, filed 5 May 2026.